Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer

Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer

(2011) H. Anderson et al.   ANNALS OF ONCOLOGY

Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors

(2011) Naoki Niikura et al.   JOURNAL OF CLINICAL ONCOLOGY

Prospective Study Evaluating the Impact of Tissue Confirmation of Metastatic Disease in Patients With Breast Cancer

(2011) Eitan Amir et al.   JOURNAL OF CLINICAL ONCOLOGY

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

An in vitro model showing adaptation to long-term oestrogen deprivation highlights the clinical potential for targeting kinase pathways in combination with aromatase inhibition

(2011) L.-A. Martin et al.   STEROIDS

Estrogen and HER-2 Receptor Discordance Between Primary Breast Cancer and Metastasis

(2010) L. Pusztai et al.   ONCOLOGIST

Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer

(2009) Matthew J. Ellis et al.   BREAST CANCER RESEARCH AND TREATMENT

Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial

(2008) Matthew J. Ellis et al.   BREAST CANCER RESEARCH AND TREATMENT

Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function

(2008) S. Massarweh et al.   CANCER RESEARCH

Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial

(2008) Mitch Dowsett et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

(2008) Robert J. Paridaens et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole

(2008) Giuseppe Viale et al.   JOURNAL OF CLINICAL ONCOLOGY